Neutralising antibodies to interferon-β in the treatment of multiple sclerosis: Cause for concern?

CNS Drugs

Volumn 11, Issue 3, 1999, Pages 225-243

  Paszner, Beatrix ^a,b   Petkau, John ^b   Oger, Joël ^a,b  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ADULT; ANTIBODY AFFINITY; ANTIGEN ANTIBODY REACTION; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYPOTHESIS; IMMUNOBLOTTING; IMMUNOGENICITY; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE; REVIEW; STANDARDIZATION; WORLD HEALTH ORGANIZATION;

EID: 0032971859     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199911030-00006     Document Type: Review

References (110)

1. Pestka S, Langer JA. Interferons and their actions. Annu Rev Biochem 1987; 56: 727-77
2. Weiner HL, Hafler DA. Immunotherapy of multiple sclerosis. Ann Neurol 1988; 23: 211-22
3. Farkkila M, Iivanainen M. Interferon in multiple sclerosis. Clin Neuropharmacol 1988; 11: 120-9
4. Sibley WA, Bamford CR, Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985; 1: 1313-5
5. Panitch HS, Bever CT, Katz E, et al. Upper respiratory tract infections trigger attacks of multiple sclerosis in patients treated with interferon [abstract]. J Neuroimmunol 1992; 35 Suppl. 1: 125
6. Booss J, Kim JH. Evidence for a viral etiology of multiple sclerosis. In: Cook SD, editor. Handbook of multiple sclerosis. New York: Marcel Dekker, 1990: 41-61
7. Cook SD, Dowling PC. Multiple sclerosis and viruses: an overview. Neurology 1980; 30: 80-91
8. Dhib-Jalbut S, McFarlin DE. Immunology of multiple sclerosis. Ann Allerg 1989; 64: 433-44
9. McFarlin DE, McFarland HF. Multiple sclerosis. N Engl J Med 1982; 307: 1183-8
10. Merrill J, Jondal M, Seeley J, et al. Decreased NK killing in patients with multiple sclerosis: an analysis at the level of the single effector cell in peripheral blood and cerebrospinal fluid in relation to the activity of the disease. Clin Exp Immunol 1982; 47: 419-30
11. Neighbour PA, Grayzel AI, Miller AE. Endogenous and interferon-augmented natural killer cell activity of human peripheral blood mononuclear cells in vitro: studies of patients with MS, SLE and rheumatoid arthritis. Clin Exp Immunol 1982; 49: 11-21
12. Antel JP, Bania MB, Reder A, et al. Activated suppressor cell dysfunction in progressive multiple sclerosis. J Immunol 1986; 137: 137-41
13. Hirsch RL. Defective autologous mixed lymphocyte reactivity in multiple sclerosis. Clin Exp Immunol 1986; 64: 107-13
14. Rose LM, Ginsberg AH, Rothstein TL, et al. Selective loss of a subset of T helper cells in active multiple sclerosis. Proc Natl Acad Sci USA 1985; 82: 7389-93
15. Selmaj K, Platerzyberk C, Rockett KA, et al. Multiple sclerosis: increased expression of interleukin-2 receptors on lymphocytes. Neurology 1986; 36: 1392-5
16. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multicenter, randomised, double-blind, placebo controlled trial. Neurology 1993; 43: 655-61
17. Banting FG, Franks WR, Gaitus S. Physiological studies in metrazol shock. VII. Anti-insulin activity of insulin-treated patients. Am J Psychiat 1938; 95: 562-6
18. Yalow RS, Berson SA. Immunologic aspects of insulin. Am J Med 1961; 31: 882-91
19. Prout TE. The antigenicity of insulin: a review. J Chron Dis 1962; 15: 879-85
20. Kahn CR, Rosenthal AS. Immunologic reactions to insulin: insulin allergy, insulin resistance, and the autoimmune insulin syndrome. Diabetes Care 1979; 2: 283-95
21. Moore WV, Leppert P. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J Clin Endocrinol Metab 1980; 51: 691-97
22. Thorner MD, Reschke J, Chitwood J, et al. Development of antibody to growth hormone-releasing factor. N Engl J Med 1985; 312: 994
23. Shapiro SS. Antibodies to blood coagulation factors. Clin Haematol 1979; 8: 207-14
24. Fireman P, Fineberg SE, Galloway JA. Development of IgE antibodies to human (recombinant DNA), porcine, and bovine insulins in diabetic subjects. Diabetes Care 1982; 5: 119-25
25. Velcovsky HG, Federlin KF. Insulin-specific IgG and IgE antibody response in type 1 diabetic subjects exclusively treated with human insulin (recombinant DNA). Diabetes Care 1982; 5: 126-8
26. Vallbracht A, Treuner J, Flehmig B, et al. Interferon-neutralising antibodies in a patient treated with human fibroblast interferon. Nature 1981; 289: 496-7
27. Gutterman JU, Fine S, Quesada J, et al. Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med 1982; 96: 549-56
28. Quesada J, Rios A, Swanson D, et al. Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol 1985; 11: 1522-8
29. Figlin R, deKernion J, Mukamel E, et al. Recombinant leukocyte A interferon (rIFN-alpha-2a) antibody development in advanced renal cell carcinoma (RCC) [abstract]. Proc Am Soc Clin Oncol 1986; 5: 222
30. Itri L, Campion M, Dennin N, et al. Incidence and clinical significance of neutralising antibodies in patients receiving recombinant interferon alpha-2a by intramuscular injection. Cancer 1987; 59: 668-74
31. Quesada J, Itri L, Gutterman J. Alpha interferons in hairy cell leukemia (HCL): a five year follow up in 100 patients [abstract]. J Interferon Res 1987; 7: 678
32. Gauci L. Management of cancer patients receiving interferon alpha-2a. Int J Cancer 1987; Suppl. 1: 21-30
33. Steis RG, Smith JW H, Urba WJ, et al. Resistance to recombinant interferon alpha-2a in hairy cell leukemia associated with neutralising anti-interferon antibodies. N Engl J Med 1988; 318: 1409-13
34. Itri LM, Sherman MJ, Palleroni AV, et al. Incidence and clinical significance of neutralising antibodies in patients receiving recombinant interferon-alpha-2a. J Interferon Res 1989; 9 Suppl. 1: S9-15
35. Porres JC, Carreno V, Ruis M, et al. Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon. J Hepatol 1989; 8: 351-7
36. Lok SF, Lai CL, Leung KY. Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection. Hepatology 1990; 12: 1266-70
37. Thomas HC, Lok AS, Carreno V, et al. Comparative study of three doses of interferon-alpha-2a in chronic active hepatitis B. The International Hepatitis Trial Group. J Viral Hepatitis 1994; 1: 139-48
38. Giannelli G, Antonelli G, Fera G, et al. Biological and clinical significance of neutralising and binding antibodies to interferon-alpha (IFN-alpha) during therapy for chronic hepatitis C. Clin Exp Immunol 1994; 97: 4-9
39. Antonelli G, Giannelli G, Currenti M, et al. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha-2 therapy. Clin Exp Immunol 1996; 104: 384-7
40. Craxi A, Di Marco V, Volpes R, et al. Anti-alpha interferon antibodies after alpha interferon treatment in patients with chronic viral hepatitis. Hepatogastroenterology 1988; 35: 304-5
41. Spiegel RJ, Spicehandler JR, Jacobs SL, et al. Low incidence of serum neutralising factors in patients receiving recombinant alpha-2b interferon (Intron A). Am J Med 1986; 80: 223-8
42. Spiegel R. The alpha interferons: clinical overview. Semin Oncol 1987; 14: 1-12
43. Leavitt R, Ratanantharathorn V, Ozer H, et al. Alpha-2b interferon in the treatment of Hodgkin's disease and non-Hodgkin's lymphoma. Semin Oncol 1987; 14: 18-23
44. Von Wussow P, Freund M, Block B, et al. Clinical significance of anti-interferon titres during interferon therapy. Lancet 1987; 2: 635-6
45. Golomb H, Ratain M, Fefer A, et al. Randomised study of the duration of treatment with interferon alpha-2b in patients with hairy cell leukemia. J Natl Cancer Inst 1988; 80: 369-73
46. Oberg K. Long-term treatment with alpha interferons of patients with malignant carcinoid tumors - the six year experience [abstract]. J Interferon Res 1988; 8: S22
47. Freund M, Von Wussow P, Diedrich H, et al. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukemia: dose dependency of response and frequency of neutralising anti-interferon antibodies. Br J Haematol 1989; 72: 350-6
48. Weck PK, Leventhal BG, Brand C, et al. Detection and incidence of neutralising antibodies to interferon-alpha-n1. J Interferon Res 1989; 9 Suppl. 1: S37-43
49. Knobler RL, Panitch HS, Braheny SL, et al. Systemic alpha-interferon therapy of multiple sclerosis. Neurology 1984; 34: 1273-9
50. Panitch HS. Systemic alpha-interferon in multiple sclerosis. Arch Neurol 1987; 44: 61-3
51. AUSTIMS Research Group. Interferon-alpha and transfer factor in the treatment of multiple sclerosis: a double-blind, placebo-controlled trial. J Neurol Neurosurg Psychiatry 1989; 52: 566-74
52. Camenga DL, Johnson KP, Alter M, et al. Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosis. Arch Neurol 1986; 43: 1239-46
53. Durelli L, Bongioanni MR, Cavallo R, et al. Chronic systemic high-dose recombinant interferon alpha-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 1994; 44: 406-13
54. Kastrukoff LF, Oger J, Hashimoto SA, et al. Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. I. Clinical and MRI evaluation. Neurology 1990; 40: 479-86
55. Kinnunen E, Timonen T, Pirttila T, et al. Effects of recombinant alpha-2b interferon therapy in patients with progressive MS. Acta Neurol Scand 1993; 87: 457-60
56. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94
57. Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralising antibodies in interferon beta-1a in multiple sclerosis. Neurology 1998; 50: 1266-72
58. Byhardt RW, Vaickus L, Witt PL, et al. Recombinant human interferon-beta (rHuIFN-beta) and radiation therapy for inoperable non-small cell lung cancer. J Interferon Cytokine Res 1996; 16: 891-902
59. Bornstein J, Pasal B, Zarfati D, et al. Recombinant human interferon-beta for condylomata acuminata: a randomised, double-blind, placebo-controlled study of intralesional therapy. Int J STD AIDS 1997; 8: 614-21
60. Dinsmore W, Jordan J, O'Mahony C, et al. Recombinant human interferon-beta in the treatment of condylomata acuminata. Int J STD AIDS 1997; 8: 622-8
61. Abdul-Ahad AK, Galazka AR, Revel M, et al. Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta-1a from mammalian cells. Cytokines Cell Mol Ther 1997; 3: 27-32
62. Abdul-Ahad AK, Shah S, Galazka A. Treatment of multiple sclerosis with interferon beta-1a. Neurology 1997; 49: 641
63. The PRISMS Study Group. Randomised, double-blind, placebo-controlled study of interferon beta 1a in relapsing-remitting multiple sclerosis. Lancet 1998; 352: 1498-504
64. Antonelli G, Bagnato F, Pozzilli C, et al. Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFNβ-1a. J Interferon Cytokine Res 1998; 18: 345-50
65. Rinehart J, Malspeis L, Young D, et al. Phase I/II trial of human recombinant beta-interferon serine in patients with renal cell carcinoma. Cancer Res 1986; 46: 5364-7
66. Konrad MW, Childs AL, Merigan TC, et al. Assessment of the antigenic response in humans to a recombinant mutant interferon beta. J Clin Immunol 1987; 7: 365-75
67. Larocca AP, Leung SC, Marcus SG, et al. Evaluation of neutralising antibodies in patients treated with recombinant interferon-beta(ser). J Interferon Res 1989; 9 Suppl. 1: S51-60
68. Knobler RL, Greenstein JI, Johnson KP, et al. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. J Interferon Res 1993; 13: 333-40
69. The IFNB Multiple Sclerosis Study Group and the UBC MS/MRI Analysis Group. Neutralising antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47: 889-94
70. Kivisakk P, Ahn GV, Tian WZ, et al. Neutralising and binding anti-interferon-beta-1b (IFN-beta-1b) antibodies during IFN-beta-1b treatment of multiple sclerosis. Mult Scler 1997; 3: 184-90
71. European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-7
72. Niijima T, Umeda T, Kuriyama M, et al. Intravesical treatment of bladder cancer with recombinant human interferon-beta: Intravesical GKT-beta Chemotherapy Research Group. Cancer Immunol Immunother 1989; 30: 81-5
73. Dummer R, Muller W, Nestle F, et al. Formation of neutralising antibodies against natural interferon-beta, but not against recombinant interferon-gamma, during adjuvant therapy for high risk malignant melanoma patients. Cancer 1991; 67: 2300-4
74. Fierlbeck G, Schreiner T, Schaber B, et al. Neutralising interferon-beta antibodies in melanoma patients treated with recombinant and natural interferon beta. Cancer Immunol Immunother 1994; 39: 263-8
75. Dore-Duffy P, Donaldson JO, Rothman BL, et al. Antinuclear antibodies in multiples sclerosis. Mult Scler 1982; 39: 504-6
76. Schuller E, Delasnerie N, Lebon P. DNA and RNA antibodies in serum and CSF of multiple sclerosis and subacute sclerosing panencephalitis patients. J Neurol Sci 1978; 37: 31-6
77. Hayes EC, Gollovin SD, Machamer CE, et al. Measles-specific antibodies in sera and cerebrospinal fluids of patients with multiple sclerosis. Infect Immun 1980; 27: 1033-7
78. Shorr J, Rostrom B, Link H. Antibodies to viral and non-viral antigens in subacute sclerosing panencephalitis and multiple sclerosis demonstrated by thin-layer polyacrylamide gel isoelectric focusing, antigen immunofixation and autoradiography. J Neurol Sci 1981; 49: 99-108
79. Salmi A, Reunanen M, Ilonen J, et al. Intrathecal antibody synthesis to virus antigens in multiple sclerosis. Clin Exp Immunol 1983; 52: 241-9
80. Larsen PD, Bloomer LC, Bray PF. Epstein-Barr nuclear antigen and viral capsid antigen antibody titers in multiple sclerosis. Neurology 1985; 35: 435-8
81. Shirodaria PV, Haire M, Fleming E, et al. Viral antibody titers: comparison in patients with multiple sclerosis and rheumatoid arthritis. Arch Neurol 1987; 44: 1237-41
82. Oger J, Roos R, Antel JP. Immunology of multiple sclerosis. Neurol Clin N Am 1983; 1 (3): 655-79
83. Paty DW, Li DKB, UBC MS/MRI Study Group, IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomised, double-blind, placebo-controlled trial. Neurology 1993; 43: 662-7
84. The IFNB Multiple Sclerosis Study Group. University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomised controlled trial. Neurology 1995; 45: 1277-85
85. Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. Ann Neurol 1998; 43: 79-87
86. Rice G, Lesaux J, Ebers G. The evolution of neutralising antibodies in patients taking beta interferon 1b [abstract]. Mult Scler 1997; 3: 344
87. Oger J, Paszner B, Paty DW. Comparison of ELISA with MxA assay for the detection of antibodies to interferon-beta and results of long-term follow-up [abstract]. Neurology 1998; 50: A342
88. Rice G, Paszner B, Oger J, et al. The evolution of neutralizing antibodies in patients treated with interferon. Neurology 1999. In press
89. Ebers GC, Oger J, Paty DW, et al. The MS PRISMS Study: prevention of relapses and disability by interferon beta 1a subcutaneously in multiple sclerosis [abstract]. Ann Neurol 1997; 42: 986
90. WHO Expert Committee on Biological Standardisation. Thirty-fifth report. WHO Technical Report Series 725. Geneva: World Health Organization, 1985
91. Pungor E Jr, Files JG, Gabe JD, et al. A novel bioassay for the determination of neutralizing antibodies to interferon beta-1b. J Interferon Res 1999. In press
92. Pachner AR. Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: plight of the practicing neurologist. Neurology 1997; 49: 647-50
93. Protzman WP, Jacobs SL, Minnicozzi M, et al. A radioimmunologic technique to screen for antibodies to alpha-2 interferon. J Immunol Meth 1984; 75: 317-23
94. Nestaas E, Files JG, Nelson JW, et al. Quantitation and characterisation of multiple sclerosis patient antibodies to interferon-beta. In: Reder AT, editor. Interferon therapy of multiple sclerosis. New York: Marcel Dekker, 1997: 523-30
95. Towbin H, Schmitz A, Jakschies D, et al. A whole blood immunoassay for the interferon-inducible human Mx protein. J Interferon Res 1992; 12: 67-74
96. Moosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Immunol Methods 1983; 65: 55-63
97. Hennes U, Jucker W, Fischer EA, et al. The detection of antibodies to recombinant interferon alfa-2a in human serum. J Biol Stand 1987; 15: 231-44
98. Oger J, Vorobeychick G, Paty DW. In Betaseron treated MS patients, in vitro immune function can be a predictor of neutralising antibody development [abstract]. Neurology 1997; 48: A80
99. Petkau J, White R. Neutralising antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis [abstract]. Mult Scler 1997; 3: 402
100. Arnason BGW. Neutralising antibodies: are they an issue? Int Mult Scler J 1997; 4: 40-42
101. Finkelman FD, Madden KB, Morris SC, et al. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anticytokine antibody complexes. J Immunol 1993; 151: 1235-44
102. Tindall RSA. Humoral immunity in myasthenia gravis: clinical correlations of anti-receptor antibody avidity and titer. Ann NY Acad Sci 1981; 377: 316-31
103. Kurtz AB, Nabarro JDN. Circulating insulin-binding antibodies. Diabetologia 1980; 19: 329-34
104. Reeves WG, Allen BR, Tattersall RB. Insulin-induced lipoatrophy: evidence for an immune pathogenesis. BMJ 1980; 280: 1500-3
105. Dixon K, Exon PD, Malins JM. Insulin antibodies and the control of diabetes. Q J Med 1975; 44: 543-53
106. Vaughan NJA, Matthews JA, Kurtz AB, et al. The bioavailability of circulating antibody-bound insulin following insulin withdrawal in type I (insulin-dependent) diabetes. Diabetologia 1983; 24: 355-8
107. Dozio N, Scavini M, Beretta A, et al. Imaging of the buffering effect of insulin antibodies in the autoimmune hypoglycemic syndrome. J Clin Endocrin Metab 1998; 83: 643-8
108. Anderson JH, Blackard WG, Goldman J, et al. Diabetes and hypoglycemia due to insulin antibodies. Am J Med 1978; 64: 868-73
109. Berson SA, Yalow RS. Quantitative aspects of the reaction between insulin and insulin-binding antibody. J Clin Invest 1959; 38: 1996-2016
110. 131I metabolism in human subjects: demonstration of insulin binding globulin in the circulation of insulin-treated subjects. J Clin Invest 1956; 35: 170-90